Embla Medical (EMBLA) investor relations material

Company Overview and Market Position

• Global leader in innovative mobility solutions, specializing in prosthetics and neuroprosthetics for various neurological disorders, with about 25% market share in a USD 2bn prosthetics market growing 6-8% annually.

• Vertically integrated with nearly 200 clinics in 12 markets, direct sales in 40 markets, and distribution in 70 more.

• Employs around 4,500 people globally and competes primarily with Ottobock; together they control two-thirds of the market.

Strategic Highlights and Industry Trends

• Achieved record sales of USD 929m in 2025, with 6% organic and 7% LCY growth, maintaining a 20% EBITDA margin.

• Named one of the World's Best Companies in Sustainable Growth 2026 by TIME Magazine for the second consecutive year.

• Operates in a niche industry benefiting from aging populations, empowered patients, digitalization, and improved healthcare access.

Innovation, R&D, and Product Development

• Invests $45–$50 million annually in R&D, representing 5–10% of sales, with USD 46m invested in 2025, focusing on advanced bionics, AI, and digitalization.

• Bionic devices significantly reduce falls, accidents, and hospitalizations, improving patient quality of life.

• Bionic penetration among amputees is increasing, with bionics representing 20-25% of the market.

• Bionic MPK market expanding through innovation, regional coverage, and new product launches like Navii/Icon and next-gen Rheo Knee.

• 3D printing and AI-driven clinic processes are transforming the sector.